 
 
Corporate office 
: 207/208, Udyog Bhavan, Sonawala Road, Goregaon (East), Mumbai – 400 063. Maharashtra, India. 
  Tel: +91 22  40332727 / 66942507  
Fax : +91 22 26860011            GSTIN: 27AALCS8686A1ZX 
 CIN: L51900MH2008PLC180452  E-mail: supriya@supriyalifescience .com   Website: www.supriyalifescience.com 
 
Factory                 : A-5/2, Lote Parshuram Industrial Area, M.I.D.C.  Tal.– Khed, Dist. – Ratnagiri, Pin :415 722, Maharashtra, India. 
                                          Tel: +91 2356 272299          Fax: +91 2356 272178           E-mail: factory@supriyalifescience.com  
 
GOVT. RECOGNISED EXPORT HOUSE 
 
 
 
September 1, 2025 
 
   To, 
 
 
 
 
 
 
 
Dear Sir (s), 
 
Sub:   Notice of the 17th Annual General Meeting, Annual Report FY 2024-25 and the 
Business Responsibility and Sustainability Report 
 
Further to our Letter dated August 30, 2025, convening that the 17th Annual General Meeting ("AGM") 
of the Members of the Company is scheduled to be held on Wednesday, September 24, 2025 at 03:00 
p.m. (IST) through Video Conferencing/ Other Audio Visual Means in accordance with relevant 
circulars issued by the Ministry of Corporate Affairs and SEBI.  
 
Pursuant to Regulation 34(1) and Regulation 30(2) of SEBI (Listing Obligations and Disclosure 
Requirements) Regulations, 2015, we are submitting herewith the Annual Report of the Company for 
the financial year 2024-25 including the Business Responsibility and Sustainability Report, along with 
the Notice of AGM, which are being sent through electronic mode to the Members of the Company, 
whose email IDs are registered with Depositories/ Company/ Registrar and Share Transfer Agent. 
 
The Annual Report along with the Notice of the AGM for the Financial Year 2024-25 is also available 
on the website of the Company at www.supriyalifescience.com under “Investor Section”. 
 
The Notice of AGM of the Company inter alia indicates the process and manner of remote e-voting/ e-
voting at the AGM and instructions for participating at the AGM through VC/OAVM. 
 
Kindly take the said information on your records. 
 
Thanking you, 
 
Yours faithfully, 
 
For Supriya Lifescience Limited 
 
 
 
Prachi Sathe 
Company Secretary & Compliance Officer 
National Stock Exchange of India Limited 
Exchange Plaza, Plot no. C/1, G Block, 
Bandra-Kurla Complex 
Bandra (E), Mumbai - 400 051 
NSE Symbol: SUPRIYA 
BSE Limited 
Phiroze Jeejeebhoy Towers, 
Dalal Street, 
Mumbai- 400 001 
Scrip Code: 543434 
Prachi Suhas 
Sathe
Digitally signed by Prachi Suhas 
Sathe 
Date: 2025.09.01 17:44:44 +05'30'
Supriya Lifescience Ltd.   |   Annual Report 2024-25   |   100
Business Responsibility and 
Sustainability Report
SECTION A: GENERAL DISCLOSURES
I.	
Details of the listed entity
1.
Corporate Identity Number (CIN) of the listed entity
L51900MH2008PLC180452
2.
Name of the listed entity
Supriya Lifescience Limited
3.
Year of incorporation
26/03/2008
4.
Registered office address
207/208, Udyog Bhavan, Sonawala Road, 
Goregaon (East), Mumbai – 400063, 
Maharashtra, India.
5.
Corporate address
207/208, Udyog Bhavan, Sonawala Road, 
Goregaon (East), Mumbai – 400063, 
Maharashtra, India.
6.
E-mail
cs@supriyalifescience.com
7.
Telephone
022-40332727
8.
Website
www.supriyalifescience.com
9.
Financial year for which reporting is being done
April 1, 2024 to March 31, 2025
10.
Name of the Stock Exchange(s) where shares are 
listed
1.	 BSE Limited (“BSE”)
2.	 The National Stock Exchange of India 
Limited (“NSE”)
11.
Paid-up Capital
H160.97 million
12.
Name and contact details (telephone, email address) 
of the person who may be contacted in case of any 
queries on the BRSR report.
Dr. Saloni Satish Wagh
Managing Director
Tel. No.: 022 4033 2727
Email id: supriya@supriyalifescience.com
13.
Reporting boundary - Are the disclosures under this 
report made on a standalone basis (i.e. only for the 
entity) or on a consolidated basis (i.e. for the entity and 
all the entities which form a part of its consolidated 
financial statements, taken together).
Standalone Basis
14.
Name of assurance provider
NA
15.
Type of assurance obtained
Not applicable
II.	 Products/services
16.	Details of business activities (accounting for 90% of the turnover):
S. No.
Description of Main Activity
Description of Business Activity
% of Turnover of the entity
1
Manufacturing of Active 
Pharmaceutical Ingredients
Manufacturing of Active 
Pharmaceutical Ingredients
98.17
SUPRIYA 
LIFESCIENCE LTD. 
Corporate Overview
Statutory Reports
Financial Section
101
17.	Products/Services sold by the entity (accounting for 90% of the entity’s Turnover):
S. No.
Product/Service
NIC Code
% of total Turnover contributed
1
Manufacturing & Sale of Active Pharmaceutical 
Ingredients
21001
98.17
III.	 Operations
18.	Number of locations where plants and/or operations/offices of the entity are situated:
Location
Number of Plants
Number of Offices
Total
National
3
1
4
International
0
0
0
19. 	Markets served by the entity:
	
a. 	 Number of locations
Locations
Number
National (No. of States)
28
International (No. of Countries)
128
	
b. 	 What is the contribution of exports as a percentage of the total turnover of the entity?
85%
	
c.	 A brief on types of customers
Our customer base comprises innovators, various generic formulation suppliers, and traders across 
various geographies.
IV.	 Employees
20.	Details as at the end of Financial Year
	
a.  Employees and workers (including differently abled):
S. 
No.
Particulars
Total
(A)
Male
Female
No (B)
% (B/A)
No (C)
% (C/A)
Employees
1
Permanent (D)
515
460
89.32%
55
10.68%
2
Other than Permanent (E)
556
554
99.64%
2
0.36%
3
Total employees (D + E)
1071
1014
94.68%
57
5.32%
Workers
1
Permanent (F)
0
0
0
2
Other than Permanent (G)
0
0
0
3
Total Workers (F + G)
0
0
0
Remarks: We do not employee workers within our organization owing to the nature of our business.
	
b.  Differently abled Employees and workers:
S. 
No.
Particulars
Total
(A)
Male
Female
No (B)
% (B/A)
No (C)
% (C/A)
Differently Abled Employees
1
Permanent (D)
0
0
0
2
Other than Permanent (E)
0
0
0
3
Total differently abled 
employees (D + E)
0
0
0
I 
I 
I 
I 
Supriya Lifescience Ltd.   |   Annual Report 2024-25   |   102
S. 
No.
Particulars
Total
(A)
Male
Female
No (B)
% (B/A)
No (C)
% (C/A)
Differently Abled Workers
1
Permanent (F)
0
0
0
2
Other than Permanent (G)
0
0
0
3
Total Workers (F + G)
0
0
0
21.	Participation/Inclusion/Representation of women
Total (A)
No. and percentage of Females
No(B)
%(B/A)
Board of Directors
10
4
40.00%
Key Management Personnel
2
1
50.00%
22.	Turnover rate for permanent employees and workers. (Disclose trends for the past 3 years)
FY 2024-25
(Turnover rate in 
current FY)
FY 2023-24
(Turnover rate in 
previous FY)
FY 2022-23
(Turnover rate in the year 
prior to the previous FY)
Male
Female
Total
Male
Female
Total
Male
Female
Total
Permanent Employees
19.1%
14.9%
18.67%
23.99%
14.46%
21%
Started tracking only from 
23-24
Permanent Workers
-
-
-
-
-
-
-
-
-
V. 	 Holding, Subsidiary and Associate Companies (including joint ventures)
23.	(a)	 Names of holding / subsidiary / associate companies / joint ventures.
S. 
No.
Name of the holding / 
subsidiary / associate 
companies / joint 
ventures (A)
Indicate whether 
holding/ subsidiary/ 
associate/ joint 
venture
% of shares 
held by listed 
entity
Does the entity indicated at 
column A, participate in the 
Business Responsibility initiatives 
of the listed entity? (Yes/No)
1
Nil
Nil
Nil
Nil
VI.	 CSR Details
24. 	Provide the following CSR details
i) 	 Whether CSR is applicable as per section 135 of Companies Act, 2013 - Yes 
ii) 	 Turnover (in H) - 7063.00 
iii) 	 Net worth (in H) - 9967.60 
~ 
SUPRIYA 
~ 
LIFESCIENCE LTD. 
I 
I 
I 
I 
I 
I 
I 
Corporate Overview
Statutory Reports
Financial Section
103
VII.	Transparency and Disclosures Compliances
25.	Complaints/Grievances on any of the principles (Principles 1 to 9) under the National Guidelines on 
Responsible Business Conduct:
Stakeholder 
group from 
whom 
complaint is 
received
Grievance Redressal 
Mechanism in Place (Yes/
No) (If Yes, then provide 
web-link for grievance 
redress policy)
FY 2024-25
FY 2023-24
Number of 
complaints 
filed 
during the 
year
Number of 
complaints 
pending 
resolution 
at close of 
the year
Remarks
Number of 
complaints 
filed 
during the 
year
Number of 
complaints 
pending 
resolution 
at close of 
the year
Remarks
Communities
Yes, weblink for policy 
can be accessed at: 
https://supriyalifescience.
com/assets/pdfs/
corporategovernance/ 
policies/Grievance%20
policy.pdf
0
0
NA
0
0
NA
Investors 
(other than 
shareholders)
Yes, weblink for policy 
can be accessed at: 
https://supriyalifescience.
com/assets/pdfs/
corporategovernance/ 
policies/Grievance%20
policy.pdf
0
0
NA
0
0
NA
Shareholders
Yes, weblink for policy 
can be accessed at: 
https://supriyalifescience.
com/assets/pdfs/
corporategovernance/ 
policies/Grievance%20
policy.pdf
0
0
NA
0
0
NA
Employees 
and workers
Yes, weblink for policy 
can be accessed at: 
https://supriyalifescience.
com/assets/pdfs/
corporategovernance/ 
policies/Grievance%20
policy.pdf
0
0
NA
0
0
NA
Customers
Yes, weblink for policy 
can be accessed at: 
https://supriyalifescience.
com/assets/pdfs/
corporategovernance/ 
policies/Grievance%20
policy.pdf
0
0
NA
0
0
NA
Value Chain 
partners
Yes, weblink for policy 
can be accessed at: 
https://supriyalifescience.
com/assets/pdfs/
corporategovernance/ 
policies/Grievance%20
policy.pdf
0
0
NA
0
0
NA
Supriya Lifescience Ltd.   |   Annual Report 2024-25   |   104
26.	Overview of the entity's material responsible business conduct issues. Please indicate material responsible 
business conduct and sustainability issues pertaining to environmental and social matters that present a 
risk or an opportunity to your business, rationale for identifying the same, approach to adapt or mitigate the 
risk along-with its financial implications, as per the following format
S. 
No.
Material 
issue 
identified
Indicate 
whether risk 
or opportunity 
(R/O)
Rationale for 
identifying the risk / 
opportunity
In case of risk, 
approach to adapt or 
mitigate
Financial implications of 
the risk or opportunity 
(Indicate positive or 
negative implications)
1
Product 
Quality and 
Safety
Opportunity
Product quality 
and safety is most 
important for retaining 
customers. Any 
gap with respect to 
customer expectations 
impacts revenue
We have stringent 
quality control and 
quality assurance 
processes which 
ensures that product 
manufactured by 
the Company meets 
quality standards 
set by itself and 
regulators
Positive
2
Product 
quality and 
safety
Opportunity
Enhancing product 
quality and safety and 
meeting the customer 
expectations will get 
more customers and 
revenue.
-
Positive
3
Research 
and 
Development
Opportunity
Investment in research 
and development 
will lead to building 
a robust product 
portfolio. We build, 
safeguard, and 
strengthen our 
research skills and 
stimulate innovative 
thinking across our 
organisation. This 
allows us to pursue 
operational excellence 
and create value for 
our stakeholders 
around the world, in 
accordance with our 
purpose of 'Caring for 
Life'.
-
Positive
4
Water 
Management
Risk
Water is becoming 
increasingly a scarce 
resource especially 
in India where the 
seasonal rainfalls are 
the primary source 
of water. Poor water 
management will 
lead to stress for 
the operations and 
employee well-being.
Adhering to the 
existing water 
management 
regulations and 
establishing goals 
for reducing water. 
Furthermore, 
continuously 
discovering and 
implementing better 
ways to measure and 
reduce water usage 
through various 
technologies and 
behaviour change 
within the workforce
Negative
SUPRIYA 
LIFESCIENCE LTD. 
Corporate Overview
Statutory Reports
Financial Section
105
S. 
No.
Material 
issue 
identified
Indicate 
whether risk 
or opportunity 
(R/O)
Rationale for 
identifying the risk / 
opportunity
In case of risk, 
approach to adapt or 
mitigate
Financial implications of 
the risk or opportunity 
(Indicate positive or 
negative implications)
5
Waste 
Management
Risk
The waste generated 
from our facilities 
has to be disposed in 
the most appropriate 
manner
The waste generated 
from our facilities 
is segregated and 
disposed through 
pollution control 
board approved 
vendors and in 
compliance with 
regulations.
Negative
6
Community 
Engagement
Opportunity
Community 
Engagement enables 
us to create shared 
value for our local 
communities, 
foster meaningful 
relationships, support 
social development, 
and contribute to the 
well-being of the areas 
in which we operate.
-
Positive
7
Data 
Privacy and 
Digitization
Risk
As a part of the 
pharmaceutical 
industry, it is 
mandatory that data 
with respect to drugs 
and drugs products 
as well as customers 
remains confidential.
We have a dedicated 
IT team to assess 
security risks that 
may arise at any 
time.
Negative
Supriya Lifescience Ltd.   |   Annual Report 2024-25   |   106
SECTION B: MANAGEMENT AND PROCESS DISCLOSURES
Policy and management processes
Disclosure Questions
P1
P2
P3
P4
P5
P6
P7
P8
P9
1.	 a.	 Whether 
your 
entity’s 
policy/
policies cover each principle and 
its core elements of the NGRBCs. 
(Yes/No)
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
1.	 b. 	 Has the policy been approved by 
the Board? (Yes/No)
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
1.	 c.	 Web Link of the Policies, if 
available
https:// 
supriyalifes-
cience. com/
assets/ pdfs/
corporat-
egovernance/ 
policies/ 
Code-of-Con-
ductfor- Di-
rectorsand- 
Senior- Man-
agement.pdf
https:// 
supriyalifes-
cience. com/
assets/ pdfs/
corporat-
egovernance/ 
policies/ Sus-
tainable%20 
procure-
ment%20 
policy.pdf
https:// 
supriyalifes-
cience. com/
assets/ pdfs/
corporat-
egovernance/ 
policies/ SLL_
Equal%20 Op-
portunity%20 
Policy.pdf
https:// 
supriyalifes-
cience. com/
assets/ pdfs/
corporat-
egovernance/ 
policies/
Business- Re-
sponsibility- 
Policy.pdf
https:// 
supriyalifes-
cience. com/
assets/ pdfs/
corporat-
egovernance/ 
policies/ 
Preventionof- 
Sexual- Har-
assment-Poli-
cy. pdf
https:// 
supriyalifes-
cience. com/
assets/ pdfs/
corporategov-
ernance/ pol-
icies/EHS%20 
Policy.pdf
https:// supri-
yalifescience. 
com/assets/ 
pdfs/corpo-
rategovern-
ance/ policies/
Code%20 
of%20Busi-
ness%20 
Conduct.pdf
https:// 
supriyalifes-
cience. com/
assets/ pdfs/
corporat-
egovernance/ 
policies/CSR-
Policy. pdf
https:// supri-
yalifescience. 
com/assets/ 
pdfs/corporat-
egovernance/ 
policies/ In-
formation%20 
Security%20
Policy. pdf
2.	 Whether the entity has translated the 
policy into procedures. (Yes / No)
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
3.	 Do the enlisted policies extend to your 
value chain partners? (Yes/No)
No
No
No
No
No
No
No
No
No
4.	 Name of the national and international 
codes/certifications/labels/ standards 
(e.g. Forest Stewardship Council, 
Fairtrade, Rainforest Alliance, Trustea) 
standards (e.g. SA 8000, OHSAS, 
ISO, BIS) adopted by your entity and 
mapped to each principle.
CDSCO, 
USFDA, 
EDQM, 
NMPA
-
-
-
-
-
-
-
ISO 
9001:2015, 
CDSCO, 
USFDA, 
EDQM, 
NMPA
~ 
SUPRIYA 
~ 
LIFESCIENCE LTD. 
I 
I 
I 
I 
I 
I 
I 
I 
Corporate Overview
Statutory Reports
Financial Section
107
Disclosure Questions
P1
P2
P3
P4
P5
P6
P7
P8
P9
5.	 Specific commitments, goals and 
targets set by the entity with defined 
timelines, if any.
We are currently in the process of assessing our ESG performance, and accordingly we will be developing commitments, goals 
and targets with defined timelines
6.	 Performance of the entity against 
the specific commitments, goals and 
targets along-with reasons in case 
the same are not met.
The performance will be periodically monitored once the goals and targets are created
Governance, leadership and oversight
7	
Statement by director responsible for the business responsibility 
report, 
highlighting 
ESG 
related 
challenges, 
targets 
and 
achievements (listed entity has flexibility regarding the placement 
of this disclosure)
Dear Stakeholders,
I am pleased to present Supriya Lifescience Ltd.’s third Business Responsibility and Sustainability 
Report. With a global presence spanning 128 countries, our mission of “Caring for Life” guides our 
operations and underpins the value we create for all stakeholders.
Over the past year, we have embedded ESG principles into our business practices, enabling us to 
enhance operational efficiency while remaining mindful of our impact on society, the environment, 
our partners, and our employees.
Environment: Within our operations, a solar project has been implemented, helping reduce our carbon 
footprint. We remain committed to adopting sustainable fuels, including renewable sources such 
as solar, biofuel, and bagasse briquettes. On the value chain front, we have further expanded our 
coverage of sustainable practices.
Social: Our strong health and safety systems ensured zero incidents of injuries this year. A majority 
of our workforce has been trained on health and safety measures, with 100% of our operations 
assessed for safety practices, extending to 60% of our value chain. We are also working continuously 
to improve access to and affordability of the products we manufacture.
Governance: Ethics, integrity, and robust corporate governance remain the foundation of our ESG 
journey. We continue to maintain stringent IT protocols and are proud to report zero incidents of data 
breaches during the year.
8.	 Details of the highest authority responsible for implementation and 
oversight of the Business Responsibility policy (ies).
Dr. Saloni Satish Wagh, Managing Director DIN: 08491410
9.	 Does the entity have a specified Committee of the Board/ Director 
responsible for decision making on sustainability related issues? 
(Yes / No). If yes, provide details.
Yes, Dr. Saloni Wagh, Managing Director, oversees the Business Responsibility and Sustainability 
initiatives of the Company
-
-
-
-
-
-
-
Supriya Lifescience Ltd.   |   Annual Report 2024-25   |   108
10.	Details of Review of NGRBCs by the Company: Indicate whether review was undertaken by Director / 
Committee of the Board/ Any other Committee
Subject for 
Review
P1
P2
P3
P4
P5
P6
P7
P8
P9
P1
P2
P3
P4
P5
P6
P7
P8
P9
Performance 
against above 
policies and 
follow up action
Director
Annually
Quarterly
Annually
Quarterly
Compliance 
with statutory 
requirements 
of relevance to 
the principles, 
and, rectification 
of any non-
compliances
Annually
Quarterly
Annually
Quarterly
11. 	Has the entity carried out independent assessment/ evaluation of the working of its policies by an external 
agency? (Yes/No). If yes, provide name of the agency.
S. no
P1
P2
P3
P4
P5
P6
P7
P8
P9
1
No
No
No
No
No
No
No
No
No
12.	 If answer to question (1) above is No i.e. not all Principles are covered by a policy, reasons to be stated
Questions
P1
P2
P3
P4
P5
P6
P7
P8
P9
The entity does not consider the Principles material to its 
business (Yes/No)
Not Applicable
The entity is not at a stage where it is in a position to formulate 
and implement the policies on specified principles (Yes/No)
The entity does not have the financial or/human and technical 
resources available for the task (Yes/No)
It is planned to be done in the next financial year (Yes/No)
Any other reason (please specify)
~ 
SUPRIYA 
~ 
LIFESCIENCE LTD. 
I 
I 
I 
I 
I 
I 
I 
I 
I 
I 
I 
I 
I 
I 
I 
I 
Corporate Overview
Statutory Reports
Financial Section
109
SECTION C: PRINCIPLE WISE PERFORMANCE DISCLOSURE
PRINCIPLE 1: Businesses should conduct and govern themselves with integrity, and in a manner that is 
Ethical, Transparent and Accountable.
Essential Indicators
1. 	 Percentage coverage by training and awareness programmes on any of the Principles during the financial year
Segment
Total number 
of training and 
awareness 
programmes 
held
Topics/principles covered under the training 
and its impact
Percentage of 
persons in respective 
category covered 
by the awareness 
programmes
Board of 
directors
2
Code 
of 
Conduct, 
Prevention 
of 
Sexual 
Harassment (POSH). This enables our Board to 
ensure that responsible, ethical and fair conduct 
is being adhered to throughout the company.
100.00%
Key Managerial 
personnel
3
Code of Conduct, Unpublished Price Sensitive 
Information 
(UPSI), 
Prevention 
of 
Sexual 
Harassment (POSH) to ensure that responsible, 
ethical and fair conduct is being adhered to 
throughout the company.
100.00%
Employees other 
than BoD and 
KMPs
3
Code 
of 
Conduct, 
Prevention 
of 
Sexual 
Harassment (POSH), Health & Safety. These 
trainings guide our employees with respect 
to their conduct in the workplace. In addition, 
Health and Safety trainings are held to ensure 
that the team is aware of the proper safety norms 
and protocols and ensure safety at all times. to 
ensure that responsible, ethical and fair conduct 
is being adhered to throughout the company.
100.00%
Workers
-
-
-
2. 	 Details of fines / penalties /punishment/ award/ compounding fees/ settlement amount paid in proceedings 
(by the entity or by directors / KMPs) with regulators/ law enforcement agencies/ judicial institutions, in the 
financial year:
Monetary
Category
NGRBC 
Principle
Name of the regulatory/ 
enforcement agencies/ 
judicial institutions
Amount 
(In INR)
Brief of 
the Case
Has an appeal 
been preferred? 
(Yes/No)
Penalty/ Fine
-
-
0
-
-
Settlement
-
-
0
-
-
Compounding fee
-
-
0
-
-
Supriya Lifescience Ltd.   |   Annual Report 2024-25   |   110
Non-Monetary
Category
NGRBC 
Principle
Name of the regulatory/ enforcement 
agencies/ judicial institutions
Brief of the 
Case
Has an appeal been 
preferred? (Yes/No)
Imprisonment
-
-
-
-
Punishment
-
-
-
-
Remarks: No cases of monetary or non-monetary fines or penalties were imposed on Supriya Lifescience
3.	 Of the instances disclosed in Question 2 above, details of the Appeal/ Revision preferred in cases where 
monetary or non-monetary action has been appealed.
S. No.
Case Details
Name of the regulatory/ enforcement agencies/ judicial institutions
1
-
-
4.	 Does the entity have an anti-corruption or anti-bribery policy? If yes, provide details in brief and if available, 
provide a web-link to the policy.
Yes. It is our policy to conduct all of our business in an honest and ethical manner. We take a zero-tolerance 
approach to bribery and corruption and are committed to acting professionally, fairly and with integrity in all 
our relationships and business dealings wherever we operate and to implementing and enforcing systems to 
counter bribery. We will uphold all laws relevant to countering
bribery and corruption. We remain bound by the applicable Indian and international laws in respect of our conduct 
both at home and abroad. The policy is a part of our Code of Conduct Policy, and can be accessed here: https://
supriyalifescience.com/assets/pdfs/corporate-overnance/policies/Code%20of%20Business%20Conduct.pdf
5.	 Number of Directors/KMPs/employees/workers against whom disciplinary action was taken by any law 
enforcement agency for the charges of bribery/ corruption:
Category
Current Financial Year
Previous Financial Year
Directors
NIL
NIL
KMPs
NIL
NIL
Employees
NIL
NIL
Workers
NIL
NIL
Remarks: None of our Directors/KMPs/employees had any disciplinary action taken against them by any law 
enforcement agency
6. 	 Details of complaints with regard to conflict of interest:
Category
Current Financial Year
Previous Financial Year
Number - 
2024-25
Remarks - 
2024-25
Number - 
2023-24
Remarks - 
2023-24
Number of complaints received in relation to 
issues of Conflict of Interest of the Directors
0
-
0
-
Number of complaints received in relation to 
issues of Conflict of Interest of the KMPs
0
-
0
-
7. 	 Provide details of any corrective action taken or underway on issues related to fines/ penalties/ action 
taken by regulators/ law enforcement agencies/ judicial institutions, on cases of corruption and conflicts of 
interest.
Nil
8. 	 Number of days of accounts payables ((Accounts payable × 365) / Cost of goods/services procured):
Particulars
Current Financial Year
Previous Financial Year
Number of days of accounts payables
111
113
Remarks: The figures for the previous year have been restated in alignment with the SEBI Disclosures
~ 
SUPRIYA 
~ 
LIFESCIENCE LTD. 
Corporate Overview
Statutory Reports
Financial Section
111
9. 	 Open-ness of business - Provide details of concentration of purchases and sales with trading houses, 
dealers, and related parties along-with loans and advances & investments, with related parties:
Parameter
Metrics
FY2024-25
FY2023-24
Concentration of 
Purchases
a. 	 Purchases from trading houses as % of total 
purchases
0.00%
4%
b. 	 Number of trading houses where purchases 
are made from
0.00%
5
c. 	 Purchases from top 10 trading houses as % of 
total purchases from trading houses
0.00%
100%
Concentration of 
Sales
a. 	 Sales to dealers / distributors as % of total 
sales
0.00%
7.18%
b. 	 Number of dealers / distributors to whom sales 
are made
0.00%
74
c. 	 Sales to top 10 dealers / distributors as % of 
total sales to dealers / distributors
0.00%
68%
Share of RPTs in
a. 	 Purchases (Purchases with related parties / 
Total Purchases)
0.00%
0.00%
b. 	 Sales (Sales to related parties / Total Sales)
0.00%
0.00%
c. 	 Loans & advances (to related parties / total 
loans & advances)
0.00%
0.00%
d. 	 Investments 
(in 
related 
parties 
/ 
total 
investments)
0.00%
0.00%
Leadership Indicators
1. 	 Awareness programmes conducted for value chain partners on any of the Principles during the financial 
year:
S. 
No.
Total number 
of awareness 
programmes held
Topics / principles 
covered under the 
training
% of value chain partners covered (by value of 
business done with such partners) under the 
awareness programmes
1
0
NA
NA
2. 	 Does the entity have processes in place to avoid/ manage conflict of interests involving members of the 
Board? (Yes/No) If Yes, provide details of the same.
Yes, the Company has in place a ‘Code of Conduct for Board Members and Senior Management’ and a ‘Related 
Party TransactionPolicy’, which are applicable to our board members. Transactions with the board members or 
any entity in which such board
members are concerned or interested are required to be approved by the Audit Committee and the Board of 
Directors. In such cases, the interested directors abstain themselves from the discussions at the meeting. The 
weblink of the abovementioned policies are mentioned below:
Code of Conduct for Board Members and Senior Management: https://supriyalifescience.com/assets/pdfs/
corporategovernance/policies/Code-of-Conduct-for-Directors-and-Senior-Management.pdf
Related Party Transaction Policy: https://supriyalifescience.com/assets/pdfs/corporate-governance/policies/
Policy-on-Related-Party-Transactions.pdf
Supriya Lifescience Ltd.   |   Annual Report 2024-25   |   112
PRINCIPLE 2: Businesses should provide goods and services in a manner that is sustainable and safe
Essential Indicators
1.	 Percentage of R&D and capital expenditure (capex) investments in specific technologies to improve the 
environmental and social impacts of product and processes to total R&D and capex investments made by the 
entity, respectively.
Particulars
Current Financial Year
Previous Financial Year
Details of improvements in 
environmental and social impacts
R&D
-
-
NA
Capex
9.08%
0.00%
Solar power plants installed at Nanded
2.	 a. 	 Does the entity have procedures in place for sustainable sourcing? (Yes/No)
Yes
	
b. 	 If yes, what percentage of inputs were sourced sustainably?
70%
3. 	 Describe the processes in place to safely reclaim your products for reusing, recycling and disposing at the 
end of life for the following:
Category
Description
(a)	 Plastics (including 
packaging)
The recycling and disposal of the plastics (including packaging) is carried out 
as per the Central Government rules and the provisions of the Plastic Waste 
Management Rules.
(b)	 E-waste
E-waste is disposed of through a registered recycler.
(c)	 Hazardous waste
Hazardous waste is disposed of to Treatment, storage, and disposal facility 
(TSDF) or authorized cement industries for further treatment and disposal or 
compressing.
(d)	 Other waste
Bio-medical waste is disposed of through authorized common bio-medical 
waste facilities.
4. 	 Whether Extended Producer Responsibility (EPR) is applicable to the entity’s activities (Yes / No). If yes, 
whether the waste collection plan is in line with the Extended Producer Responsibility (EPR) plan submitted 
to Pollution Control Boards? If not, provide steps taken to address the same.
Not Applicable
Leadership Indicators
1.	 Has the entity conducted Life Cycle Perspective / Assessments (LCA) for any of its products (for 
manufacturing industry) or for its services (for service industry)? If yes, provide details:
S. 
No.
NIC Code
Name of 
Product /
Service
% of total 
Turnover 
contributed
Boundary for 
which the Life 
Cycle Perspective 
/ Assessment was 
conducted
Whether 
conducted by 
independent 
external agency 
(Yes/No)
Results 
communicated in 
public domain (Yes/
No) If yes, provide 
the web-link.
1
 NA
SUPRIYA 
LIFESCIENCE LTD. 
Corporate Overview
Statutory Reports
Financial Section
113
2.	 If there are any significant social or environmental concerns and/or risks arising from production or disposal 
of your products / services, as identified in the Life Cycle Perspective / Assessments (LCA) or through any 
other means, briefly describe the same along-with action taken to mitigate the same.
S. No.
Name of Product / Service
Description of the risk / concern
Action Taken
1
-
-
-
3.	 Percentage of recycled or reused input material to total material (by value) used in production (for 
manufacturing industry) or providing services (for service industry).
S. 
No.
Indicate input material
Recycled or re-used input material to total material
FY2024-25
FY2023-24
1
4. 	 Of the products and packaging reclaimed at end of life of products, disclose the amount (in metric tonnes) 
reused, recycled, and safely disposed:
FY2024-25
FY2023-24
Re-Used
Recycled
Safely Disposed
Re-Used
Recycled
Safely Disposed
Plastics (including 
packaging)
0
0
0
0
0
0
E-waste
0
0
0
0
0
0
Hazardous waste
0
0
0
0
0
0
Other waste
0
0
0
0
0
0
5. 	 Reclaimed products and their packaging materials (as percentage of products sold) for each product 
category.
S. No.
Indicate product category
Reclaimed products and their packaging materials as % of total 
products sold in respective category
PRINCIPLE 3: Businesses should respect and promote the well-being of all employees, including those in 
their value chains
Essential Indicators
1.	 a. 	 Details of measures for the well-being of employees:
% of employees covered by
Total 
(A)
Health  
insurance
Accident  
insurance
Maternity 
benefits
Paternity 
benefits
Day Care 
facilities
Number 
(B)
%  
(B / A)
Number 
(C)
%  
(C / A)
Number 
(D)
%  
(D / A)
Number 
(E)
%  
(E / A)
Number 
(F)
%  
(F / A)
Permanent Employees
Male
460
0
0.00%
460
100.00%
0
0.00%
0
0.00%
0
0.00%
Female
55
0
0.00%
55
100.00%
55
100%
0
0.00%
0
0.00%
Total
515
0
0.00%
515
100.00%
55
100%
0
0.00%
0
0.00%
Supriya Lifescience Ltd.   |   Annual Report 2024-25   |   114
% of employees covered by
Total 
(A)
Health  
insurance
Accident  
insurance
Maternity 
benefits
Paternity 
benefits
Day Care 
facilities
Number 
(B)
%  
(B / A)
Number 
(C)
%  
(C / A)
Number 
(D)
%  
(D / A)
Number 
(E)
%  
(E / A)
Number 
(F)
%  
(F / A)
Other than permanent Employees
Male
554
554
100.00%
554
100.00%
0
0.00%
0
0.00%
0
0.00%
Female
2
2
100.00%
2
100.00%
2
100%
0
0.00%
0
0.00%
Total
556
556
100.00%
556
100.00%
2
100%
0
0.00%
0
0.00%
b. 	 Details of measures for the well-being of workers:
% of workers covered by
Total 
(A)
Health  
insurance
Accident  
insurance
Maternity 
benefits
Paternity 
benefits
Day Care 
facilities
Number 
(B)
%  
(B / A)
Number 
(C)
%  
(C / A)
Number 
(D)
%  
(D / A)
Number 
(E)
%  
(E / A)
Number 
(F)
%  
(F / A)
Permanent Workers
Male
0
0
0
0
0
0
Female
0
0
0
0
0
0
Total
0
0
0
0
0
0
Other than permanent Workers
Male
0
0
0
0
0
0
Female
0
0
0
0
0
0
Total
0
0
0
0
0
0
c. 	 Spending on measures towards well-being of employees and workers (including permanent and other than 
permanent):
Particulars
Current  
Financial Year
Previous 
Financial Year
Cost incurred on wellbeing measures as a % of total revenue of the 
company
0.29%
0.21%
2. 	 Details of retirement benefits, for Current Financial Year and Previous Financial Year.
Benefits
FY2024-25
FY2023-24
No. of 
employees 
covered as 
a % of total 
employees. 
(CY)
No. of 
workers 
covered as 
a % of total 
workers. 
(CY)
Deducted and 
deposited 
with the 
authority 
(Y/N/N.A.). 
(CY)
No. of 
employees 
covered as 
a % of total 
employees. 
(PY)
No. of 
workers 
covered as 
a % of total 
workers. 
(PY)
Deducted and 
deposited 
with the 
authority 
(Y/N/N.A.). 
(PY)
PF
8.96%
Y
9.79%
Y
Gratuity
9.34%
Y
10.64%
Y
ESI
4.01%
Y
4.57%
Y
~ 
SUPRIYA 
~ 
LIFESCIENCE LTD. 
I I 
I 
I 
I 
I 
I 
I 
I 
I 
I 
I 
I 
I 
I 
I 
I 
I 
I 
I 
I 
Corporate Overview
Statutory Reports
Financial Section
115
3	
Are the premises / offices of the entity accessible to differently-abled employees and workers, as per the 
requirements of the Rights of Persons with Disabilities Act, 2016? If not, whether any steps are being taken 
by the entity in this regard.
No, our premises are currently not accessible to differently abled employees and workers. We have facilities 
available at our office for easy access through Lifts for differently abled employees
4.	 Does the entity have an equal opportunity policy as per the Rights of Persons with Disabilities Act, 2016? If 
so, provide a web-link to the policy.
Yes.
https://supriyalifescience.com/assets/pdfs/corporate-governance/policies/SLL_Equal%20Opportunity%20
Policy.pdf
5.	 Return to work and Retention rates of permanent employees and workers that took parental leave.
Gender
Permanent employees
Permanent workers
Return to work rate
Retention rate
Return to work rate
Retention rate
Male
-
-
-
-
Female
-
-
-
-
Total
-
-
-
-
Remark: None of the employees took parental leave in the year of reporting
6. 	 Is there a mechanism available to receive and redress grievances for the following categories of employees 
and worker? If yes, give details of the mechanism in brief.
Category
Yes/No (If Yes, then give details of the mechanism in brief)
Permanent Workers
All employees are covered under the Grievance Redressal Policy, in which the 
HR department assists the employees to fill out a grievance form, post which 
mediation processes are organized. The services of an investigator may be called 
upon when necessary. Employees are kept informed throughout the process, and 
once a resolution is reached, they have the ability to appeal the decision if required.
Other than Permanent 
Workers
All employees are covered under the Grievance Redressal Policy, in which the 
HR department assists the employees to fill out a grievance form, post which 
mediation processes are organized. The services of an investigator may be called 
upon when necessary. Employees are kept informed throughout the process, and 
once a resolution is reached, they have the ability to appeal the decision if required.
Permanent Employees
All employees are covered under the Grievance Redressal Policy, in which the 
HR department assists the employees to fill out a grievance form, post which 
mediation processes are organized. The services of an investigator may be called 
upon when necessary. Employees are kept informed throughout the process, and 
once a resolution is reached, they have the ability to appeal the decision if required.
Other than Permanent 
Employees
All employees are covered under the Grievance Redressal Policy, in which the 
HR department assists the employees to fill out a grievance form, post which 
mediation processes are organized. The services of an investigator may be called 
upon when necessary. Employees are kept informed throughout the process, and 
once a resolution is reached, they have the ability to appeal the decision if required.
Supriya Lifescience Ltd.   |   Annual Report 2024-25   |   116
7. 	 Membership of employees and worker in association(s) or Unions recognised by the listed entity:
Category
FY2024-25
FY2023-24
Total 
employees 
/ workers in 
respective 
category (A)
No. of employees 
/ workers in 
respective 
category, who 
are part of 
association(s) or 
Union (B)
% (B / A)
Total 
employees 
/ workers in 
respective 
category (C)
No.of employees 
/ workers in 
respective 
category, who 
are part of 
association(s)or 
Union (D)
% (B / A)
Total Permanent 
Employees
515
515
100.00%
420
0
0.00%
Male
460
460
100.00%
380
0
0.00%
Female
55
55
100.00%
40
0
0.00%
Total Permanent 
Workers
0
0
Male
0
0
0
0
Female
0
0
0
0
8. 	 Details of training given to employees and workers:
Category
FY2024-25
FY2023-24
Total
(A)
On Health and 
safety measures
On Skill 
upgradation
Total
(D)
On Health and 
safety measures
On Skill 
upgradation
No. (B)
% (B / A)
No. (C)
% (C / A)
No. (E)
% (E / D)
No. (F)
% (F / D)
Employees
Male
1014
1014
100.00%
1014
100.00%
895
871
97.32%
895
100.00%
Female
57
57
100.00%
57
100.00%
45
41
91.11%
45
100.00%
Total
1071
1071
100.00%
1071
100.00%
940
912
97.02%
940
100.00%
Workers
Male
0
0
NA
0
NA
0
0
NA
0
NA
Female
0
0
NA
0
NA
0
0
NA
0
NA
Total
0
0
NA
0
NA
0
0
NA
0
NA
9. 	 Details of performance and career development reviews of employees and workers:
Category
FY2024-25
FY2023-24
Total (A)
No. (B)
% (B / A)
Total (C)
No. (D)
%(D / C)
Employees
Male
1014
1014
100.00%
895
742
82.91%
Female
57
57
100.00%
45
30
66.67%
Total
1071
1071
100.00%
940
772
82.13%
Workers
Male
0
0
NA
0
0
NA
Female
0
0
NA
0
0
NA
Total
0
0
NA
0
0
NA
~ 
SUPRIYA 
~ 
LIFESCIENCE LTD. 
I 
I 
I 
I 
I 
Corporate Overview
Statutory Reports
Financial Section
117
10.	a. 	 Whether an occupational health and safety management system has been implemented by the entity? 
(Yes/ No). If yes, the coverage such system?
Yes. Workplace hazards and sources of potential harm or damage in any work environment are identified, 
investigated, removed and incidents taking place in the workplace are stopped. The policy is designed 
and implemented to prevent workplace-related injuries and ill-health for workers and to provide a safe and 
healthy workplace. Our health and safety management system covers all locations, and all staff.
b. 	 What are the processes used to identify work-related hazards and assess risks on a routine and non-
routine basis by the entity?
We are using Hazard Identification and Risk Assessment (HIRA) which is systematic process used to identify 
potential hazards in the workplace, assess the associated risks, and implement controls to mitigate or 
eliminate those risks.
c. 	 Whether you have processes for workers to report the work related hazards and to remove themselves 
from such risks. (Y/N)
Yes, Risk assessment and HAZOP conducting and identifying hazards and evaluating any associated risks 
within a workplace, then implementing reasonable control measures to remove or reduce them.
d. 	 Do the employees/ worker of the entity have access to non-occupational medical and healthcare 
services? (Yes/ No)
Yes, the employees and workers have access to non-occupational medical and healthcare services. provided 
group medical insurance in case of accidents, premedical checkup, preventive medical, OHC etc.
11. 	Details of safety related incidents:
Safety Incident/Number
Category
FY2024-25
FY2023-24
Lost Time Injury Frequency Rate (LTIFR)  
(per one million-person hours worked)
Employees
0
0
Workers
0
0
Total recordable work-related injuries
Employees
0
0
Workers
0
0
No. of fatalities
Employees
0
0
Workers
0
0
High consequence work-related injury or ill-health 
(excluding fatalities)
Employees
0
0
Workers
0
0
Number of Permanent Disabilities
Employees
0
0
Workers
0
0
12. 	Describe the measures taken by the entity to ensure a safe and healthy work place.
We make every effort to integrate safety into all business processes. Our safety and health management system 
is based on the principle of plan, do, check and act. Credible risks are evaluated, and adequate actions are 
taken to mitigate this risk. Safety incidents are reported, investigated and lessons learnt are communicated 
widely within the organization. This is underpinned by continuous improvement objectives and periodic reviews 
through the Safety and Health Committees, each headed by a Management Committee Member to ensure that 
we achieve our targets. A robust audit mechanism is in place to verify compliance to internal standards as well 
statutory requirements. A safety culture is promoted by undertaking behavioural interventions at all levels and 
disseminating the importance of safety as a personal value. Positive safety behaviours are promoted, while 
unsafe behaviours are corrected through established procedures. A comprehensive emergency response plan 
and related facilities are maintained at all sites and employees are trained to respond accordingly.
Supriya Lifescience Ltd.   |   Annual Report 2024-25   |   118
13. 	Number of Complaints on the following made by employees and workers:
FY2024-25
FY2023-24
Filed during 
the year
Pending 
resolution at the 
end of year
Remarks
Filed during 
the year
Pending 
resolution at 
the end of year
Remarks
Working Conditions
2
0
NA
4
1
NA
Health & Safety
0
0
NA
1
0
NA
14. 	Assessments for the year:
Category
% of your plants and offices that were assessed  
(by entity or statutory authorities or third parties)
Health and safety practices
100.00%
Working Conditions
100.00%
15. 	Provide details of any corrective action taken or underway to address safety-related incidents (if any) and on 
significant risks / concerns arising from assessments of health & safety practices and working conditions.
We are investigating all recordable incidents to identify the root causes and implement actions to avoid 
repeat incidents. We ensure closure of all gaps identified during internal and external audits/assessments in a 
timely manner.
Leadership Indicators
1. 	 Does the entity extend any life insurance or any compensatory package in the event of death of (A) Employees 
(Y/N) (B) Workers (Y/N).
Yes
2. 	 Provide the measures undertaken by the entity to ensure that statutory dues have been deducted and 
deposited by the value chain partners.
PF, ESIC, PT, & MLWF statutory dues deducted and deposited governing authority on monthly basis.
3. 	 Provide the number of employees or workers having suffered high consequence work-related injury / 
ill-health / fatalities (as reported in EI-11 above), who have been are rehabilitated and placed in suitable 
employment or whose family members have been placed in suitable employment.
Total no. of affected employees/ 
workers
No. of employees/workers that are 
rehabilitated and placed in suitable 
employment or whose family members 
have been placed in suitable employment
FY2024-25
FY2023-24
FY2024-25
FY2023-24
Employees
0
0
0
0
Workers
0
0
0
0
4. 	 Does the entity provide transition assistance programs to facilitate continued employability and the 
management of career endings resulting from retirement or termination of employment? (Yes/ No)
Yes
5.	 Details on assessment of value chain partners:
Category
% of value chain partners  
(by value of business done with such partners) that were assessed
Health and safety practices
NA
Working Conditions
SUPRIYA 
LIFESCIENCE LTD. 
Corporate Overview
Statutory Reports
Financial Section
119
6. 	 Provide details of any corrective actions taken or underway to address significant risks / concerns arising 
from assessments of health and safety practices and working conditions of value chain partners.
No corrective actions were required to be undertaken.
PRINCIPLE 4: Businesses should respect the interests of and be responsive to all its stakeholders
Essential Indicators
1.	 Describe the processes for identifying key stakeholder groups of the entity.
The stakeholder groups are identified as part of the stakeholder engagement mechanism, built on the principles 
of inclusivity, accountability, and responsibility. Presently, the given stakeholders group have the immediate 
impact on the operations and working of the Company. The primary stakeholders in Company include investors, 
board members, workers, clients, suppliers, the community, and regulators.
2. 	 List stakeholder groups identified as key for your entity and the frequency of engagement with each 
stakeholder group.
S. 
No.
Stakeholder 
Group
Whether 
identified as 
Vulnerable & 
Marginalized 
Group (Yes/No)
Channels of 
communication
Frequency of 
engagement
Purpose and scope of 
engagement
1
Investors/ 
Shareholders
No
Investor and analyst 
meetings, Annual 
General Meeting, 
Stock Exchange 
Intimations, Annual 
Report, Email, 
Company Website
Annually/ 
Half yearly/ 
Quarterly/ 
Need-based
Keeping communication 
channels open with 
analysts and investor 
community helps to 
connect them with the 
Company
2
Employees
No
Email & Website, In 
person meetings
Regular and 
need-based
Innovation, Operational 
efficiency, improvement 
area, Long-term strategy 
plans, training and 
awareness, responsible 
marketing, brand 
communication, health, 
safety and engagement 
initiatives.
3
Customers
No
Emails, brochures, 
website and meetings 
(physical and virtual).
Based on 
business needs
To keep the customers 
informed about our 
products and services 
and to understand the 
business needs
4
Value chain 
Partner
No
Email & Website, In 
person meetings, 
con-call meetings, 
Vendor meets
Based on 
business needs
To ensure timely supply 
of goods and services 
in order to maintain 
business continuity 
sustainably
5
Government 
and 
Regulators
No
E-mails and letters, 
Conferences, Industry 
forums, Regulatory 
filings, Meetings 
with officials, and 
Representations
On a need basis To maintain regular 
engagement, 
communications and 
advocacy with Regulatory 
Authorities, to understand 
and brief on matters 
pertaining to regulatory 
changes from time to time
Supriya Lifescience Ltd.   |   Annual Report 2024-25   |   120
S. 
No.
Stakeholder 
Group
Whether 
identified as 
Vulnerable & 
Marginalized 
Group (Yes/No)
Channels of 
communication
Frequency of 
engagement
Purpose and scope of 
engagement
6
Communities
Yes
Through CSR 
projects initiatives 
and meetings and 
through e-mail 
communications
On a need basis Livelihood support, 
disaster relief, CSR 
activities with a 
focus on health, 
education, sanitation 
and infrastructure 
development.
Leadership Indicators
1. 	 Provide the processes for consultation between stakeholders and the Board on economic, environmental, 
and social topics or if consultation is delegated, how is feedback from such consultations provided to the 
Board.
The Company management regularly interacts with key stakeholders i.e. investors, customers, suppliers, 
employees, etc. and has constantly prioritized the engagement with stakeholders as demonstrated by 
its corporate philosophy in conducting business with morality and responsibility towards society as a good 
citizen, implementing the code of conduct as a basis of work for all employees, employing the good corporate 
governance as a principle of management and exercising the sustainable development.
2. 	 Whether stakeholder consultation is used to support the identification and management of environmental, 
and social topics (Yes / No). If so, provide details of instances as to how the inputs received from stakeholders 
on these topics were incorporated into policies and activities of the entity.
No.
3. 	 Provide details of instances of engagement with, and actions taken to, address the concerns of vulnerable/ 
marginalized stakeholder groups.
Not Applicable
PRINCIPLE 5: Businesses should respect and promote human rights
Essential Indicators
1. 	 Employees and workers who have been provided training on human rights issues and policy(ies) of the 
entity:
Category
FY2024-25
FY2023-24
Total (A)
No. of employees 
/ workers 
covered (B)
%(B / A)
Total(C)
No. of employees 
/ workers 
covered (D)
%(D / C)
Employees
Permanent
515
515
100.00%
420
420
100.00%
Other than 
permanent
556
556
100.00%
520
520
100.00%
Total Employees
1071
1071
100.00%
940
940
100.00%
~ 
SUPRIYA 
~ 
LIFESCIENCE LTD. 
Corporate Overview
Statutory Reports
Financial Section
121
Category
FY2024-25
FY2023-24
Total (A)
No. of employees 
/ workers 
covered (B)
%(B / A)
Total(C)
No. of employees 
/ workers 
covered (D)
%(D / C)
Workers
Permanent
0
0
0
0
Other than 
permanent
0
0
0
0
Total Workers
0
0
0
0
2. 	 Details of minimum wages paid to employees:
Category
FY2024-25
FY2023-24
Total
(A)
Equal to Minimum 
Wage
More than 
Minimum Wage
Total
(D)
Equal to 
Minimum Wage
More than 
Minimum Wage
No. (B)
% (B /A)
No. ( C)
%(C / A)
No.(E)
% (E /D)
No.(F)
% (F /D)
Employees
Permanent
515
101
19.61%
414
80.39%
420
0
0.00%
420
100.00%
Male
460
81
17.61%
379
82.39%
380
0
0.00%
380
100.00%
Female
55
20
36.36%
35
63.64%
40
0
0.00%
40
100.00%
Other than 
Permanent
556
556
100.00%
0
0.00%
520
492
94.62%
28
5.38%
Male
554
554
100.00%
0
0.00%
515
491
95.34%
24
4.66%
Female
2
2
100.00%
0
0.00%
5
1
20.00%
4
80.00%
Workers
Permanent
0
0
NA
0
NA
0
0
NA
0
NA
Male
0
0
NA
0
NA
0
0
NA
0
NA
Female
0
0
NA
0
NA
0
0
NA
0
NA
Other than 
Permanent
0
0
NA
0
NA
0
0
NA
0
NA
Male
0
0
NA
0
NA
0
0
NA
0
NA
Female
0
0
NA
0
NA
0
0
NA
0
NA
3. 	 a.	 Details of remuneration/salary/wages: Median remuneration/wages:
Male
Female
Number
Median 
remuneration/ 
salary/ wages of 
respective category
Number
Median remuneration/ 
salary/ wages of 
respective category
Board of Directors (BoD)
2
63.57
3
30.00
Key Managerial Personnel
2
26.69
1
1.51
Employees other than BoD 
and KMP
488
0.38
53
4
Workers
0
0
0
0
I 
I 
Supriya Lifescience Ltd.   |   Annual Report 2024-25   |   122
b. 	 Provide information on Gross wages paid to females by the entity:
Particulars
Current  
Financial Year
Previous 
Financial Year
Gross wages paid to females as % of total wages
0.14%
0.15%
4. 	 Do you have a focal point (Individual/ Committee) responsible for addressing human rights impacts or issues 
caused or contributed to by the business? (Yes/No)
No
5. 	 Describe the internal mechanisms in place to redress grievances related to human rights issues.
At Supriya Lifescience Ltd., periodic visits are done by the Management to all of the facilities to ensure that all 
policies and procedures are being adhered to. We provide human rights training to our staff, and in addition, 
the premises are constantly monitored using CCTV cameras to ensure that there are no human rights violations 
occurring. Lastly, in case of any grievance, the staff approaches the management with respect to any grievances, 
and the management is responsible for redressal of the same.
6. 	 Number of Complaints on the following made by employees and workers:
FY2024-25
FY2023-24
Filed during 
the year
Pending 
resolution at the 
end of year
Remarks
Filed during 
the year
Pending 
resolution at 
the end of year
Remarks
Sexual Harassment
0
0
0
0
0
0
Discrimination at 
workplace
0
0
0
0
0
0
Child Labour
0
0
0
0
0
0
Forced Labour/
Involuntary Labour
0
0
0
0
0
0
Wages
0
0
0
0
0
0
Other human rights 
related issues
0
0
0
0
0
0
7. 	 Complaints filed under the Sexual Harassment of Women at Workplace (Prevention, Prohibition and 
Redressal) Act, 2013:
Particulars
Current 
Financial Year
Previous 
Financial Year
Total Complaints reported under Sexual Harassment on of Women 
at Workplace (Prevention, Prohibition and Redressal) Act, 2013 
(POSH)
0
0
Complaints on POSH as a % of female employees / workers
0
0
Complaints on POSH upheld
0
0
8. 	 Mechanisms to prevent adverse consequences to the complainant in discrimination and harassment cases.
We are committed to ensuring a workplace that is safe for all of our staff and free from discrimination. Should 
there be any complaint filed with respect to discrimination or harassment, an Internal Complaints Committee 
oversees the process, in a way that ensures that the confidentiality of the Complainant is maintained throughout. 
Stringent protocols are followed to ensure that the complainant does not face any adverse consequences during 
the process or after.
SUPRIYA 
LIFESCIENCE LTD. 
Corporate Overview
Statutory Reports
Financial Section
123
9. 	 Do human rights requirements form part of your business agreements and contracts? (Yes/No)
Yes
10. 	Assessments for the year:
Category
% of your plants and offices that were assessed  
(by entity or statutory authorities or third parties)
Child labour
100.00%
Forced/involuntary labour
100.00%
Sexual harassment
100.00%
Discrimination at workplace
100.00%
Wages
100.00%
11. 	Provide details of any corrective actions taken or underway to address significant risks / concerns arising 
from the assessments at Question 10 above.
No corrective actions were required to be undertaken as no significant risks/concerns arose from the assessments
Leadership Indicators
1. 	 Details of a business process being modified / introduced as a result of addressing human rights grievances/
complaints.
NA
2. 	 Details of the scope and coverage of any human rights due-diligence conducted.
Not applicable
3. 	 Is the premise/office of the entity accessible to differently abled visitors, as per the requirements of the 
Rights of Persons with Disabilities Act, 2016?
No
4. 	 Details on assessment of value chain partners:
Category
% of value chain partners (by value of business done with such partners) 
that were assessed
Sexual harassment
NA
Discrimination at workplace
Child labour
Forced/involuntary labour
Wages
5. 	 Provide details of any corrective actions taken or underway to address significant risks / concerns arising 
from the assessments at LI-4 above.
Not applicable
Supriya Lifescience Ltd.   |   Annual Report 2024-25   |   124
PRINCIPLE 6: Businesses should respect and make efforts to protect and restore the environment
Essential Indicators
1. 	 Details of total energy consumption in GigaJoules (GJ):
Parameter
FY 2024-25
FY 2023-24
From renewable sources
Total electricity consumption (A)
22,516.124
3,287.95
Total fuel consumption (B)
75,517.72
73,534.35
Energy consumption through other sources ( C )
Total energy consumed from renewable sources (A+B+C)
98,033.84
76,822.30
From non-renewable sources
Total electricity consumption (D)
67,002.13
55,750.88
Total fuel consumption (E)
3287.88
2,969.14
Energy consumption through other sources (F)
Total energy consumed from non-renewable sources (D+E+F)
70,290.01
58,720.03
Total energy consumed (A+B+C+D+E+F)
1,68,323.85
1,35,542.32
Energy intensity per rupee of turnover (Total energy 
consumption/ turnover in rupees)
24.167 GJ / 
Million
23.33 GJ / Million
Energy intensity per rupee of turnover adjusted for Purchasing 
Power Parity (PPP) (Total energy consumed / Revenue from 
operations adjusted for PPP)
499.30 GJ / 
Million
522.57 GJ/Million
Energy intensity in terms of physical output
0.16 GJ / 
Production in Kgs
0.12 GJ / 
Production in Kgs
1. 	 Indicate if any independent assessment/evaluation/assurance for energy has been conducted by an external 
agency. If Yes, provide the name of the agency: No
2. 	 Does the entity have any sites / facilities identified as designated consumers (DCs) under the Performance, 
Achieve and Trade (PAT) Scheme of the Government of India? (Y/N) If yes, disclose whether targets set 
under the PAT scheme have been achieved. In case targets have not been achieved, provide the remedial 
action taken, if any.
No
3. 	 Provide details of the following disclosures related to water:
Parameter
FY 2024-25
FY 2023-24
Water withdrawal by source (in kilolitres)
(i) 	 Surface water
0.00
0.00
(ii)	 Groundwater
0.00
0.00
(iii)	 Third party water
124289.00
119009.00
(iv)	Seawater / desalinated water
0.00
0.00
(v) 	Others
0.00
0.00
Total volume of water withdrawal (in kilolitres) (i + ii + iii + iv + v)
124289.00
119009.00
Total volume of water consumption (in kilolitres)
42842.00
44484.00
Water intensity per rupee of turnover  
(Water consumed / turnover)
6.15 KL / Million
7.80 KL / Million
SUPRIYA 
LIFESCIENCE LTD. 
Corporate Overview
Statutory Reports
Financial Section
125
Parameter
FY 2024-25
FY 2023-24
Water intensity per rupee of turnover adjusted for Purchasing 
Power Parity (PPP) (Total water consumption / Revenue from 
operations adjusted for PPP)
Infinity KL / Million
Infinity KL / Million
Water intensity in terms of physical output
0.04 KL / 
Production in Kgs
0.05 KL / 
Production in Kgs
Water intensity (optional) – the relevant metric may be selected 
by the entity. KL / of
Infinity
Infinity
3. 	 Indicate if any independent assessment/ evaluation/assurance has been carried out by an external agency? 
(Y/N) If yes, name of the external agency. -
No. 
4. 	 Provide the following details related to water discharged: Water discharge by destination and level of 
treatment (in kilolitres)
Parameter
FY 2024-25
FY 2023-24
Water discharge by destination and level of treatment (in kilolitres)
(i) 	 To Surface water
	
-  No treatment
0.00
0.00
With treatment – please specify level of treatment
0.00
0.00
(ii) 	To Groundwater
	
-  No treatment
0.00
0.00
With treatment – please specify level of treatment
0.00
0.00
(iii) 	To Seawater
	
-  No treatment
0.00
0.00
With treatment – please specify level of treatment
0.00
0.00
(iv)	Sent to third-parties
	
-  No treatment
0.00
0.00
With treatment – please specify level of treatment
81447.00
In-House Effluent 
treatment Plant
74525.00
In-House Effluent 
treatment Plant
(v)	 Others
	
- No treatment
0.00
0.00
With treatment – please specify level of treatment
0.00
0.00
Total water discharged (in kilolitres)
81447.00
74525.00
4. 	 Indicate if any independent assessment/ evaluation/assurance has been carried out by an external agency? 
(Y/N) If yes, name of the external agency. -
No
5. 	 Has the entity implemented a mechanism for Zero Liquid Discharge? If yes, provide details of its coverage 
and implementation.
No
6. 	 Please provide details of air emissions (other than GHG emissions) by the entity:
Parameter
Please specify 
unit
Current 
Financial Year
Previous 
Financial Year
NOx
Mg/NM3
42.5
124.3
SOx
Mg/NM3
19.13
148.2
Particulate matter (PM)
Mg/NM3
65.6
255.5
Persistent organic pollutants (POP)
Mg/NM3
0.00
0.00
Volatile organic compounds (VOC)
Mg/NM3
0.00
0.00
Hazardous air pollutants (HAP)
Mg/NM3
0.00
0.00
Others – please specify in the remark section
Mg/NM3
0.00
0.00
Supriya Lifescience Ltd.   |   Annual Report 2024-25   |   126
6.	 Indicate if any independent assessment/evaluation/assurance for Air emissions has been conducted by an 
external agency. If Yes, provide the name of the agency:
Yes. Padmaja Aero biological pvt ltd
7. 	 Provide details of greenhouse gas emissions (Scope 1 and Scope 2) in MTCO2e:
Parameter
Unit
Current 
Financial Year
Previous Financial 
Year
Total Scope 1 emissions (Break-up of the GHG 
into CO2, CH4, N2O, HFCs, PFCs, SF6, NF3, if 
available)
TCO₂e
480.49
451.01
Total Scope 2 emissions (Break-up of the GHG 
into CO2, CH4, N2O, HFCs, PFCs, SF6, NF3, if 
available)
TCO₂e
13,425.26
10,995.31
Total Scope 1 and Scope 2 emission intensity 
per rupee of turnover
TCO₂e / rupee 
of turnover
0.0000 TCO₂e / 
Million
0.0000 TCO₂e / 
Million
Total Scope 1 and Scope 2 emission intensity 
per rupee of turnover adjusted for Purchasing 
Power Parity (PPP)
TCO₂e / rupee 
of turnover
NaN TCO₂e / 
Million
NaN TCO₂e / 
Million
Total Scope 1 and Scope 2 emission intensity 
in terms of physical output
TCO₂e / rupee 
of turnover
0.0000 TCO₂e / 
Production in Kgs
0.0000 TCO₂e / 
Production in Kgs
Total Scope 1 and Scope 2 emission intensity 
(optional) – the relevant metric may be 
selected by the entity
TCO₂e / of
NaN
NaN
7. 	 Indicate if any independent assessment/evaluation/assurance for GHG Emissions (Scope 1 and 2) has been 
conducted by an external agency. If Yes, provide the name of the agency: -
No.
8. 	 Does the entity have any project related to reducing Green House Gas emission? If Yes, then provide details.
Yes
9 	 Provide details related to waste management by the entity for the Current Financial Year:
Parameter
FY2024-25
FY2023-24
Total Waste generated (in metric tonnes)
Plastic waste (A)
12.0000
12.0000
E-waste(B)
0.1060
0.0000
Bio-medical waste (C)
0.0008
0.0001
Construction and demolition waste (D)
0.0000
15.00
Battery waste (E)
0.0000
0.31
Radioactive waste (F)
0.0000
0.0000
Other Hazardous waste.Please specify, if any. (G)
75.6000
13.00
Other Non-hazardous waste generated (H). Please specify, if any.
(Break-up by composition i.e. by materials relevant to the sector)
0.0000
320.00
Total (A + B + C + D + E + F + G + H)
87.7068
360.31
Waste intensity per rupee of turnover (Total Waste Generated / 
Revenue from operations)
0.0125 MT / 
Million
0.0620 MT / 
Million INR
Waste intensity per rupee of turnover adjusted for Purchasing 
Power Parity (PPP) (Total Waste Generated / Revenue from 
operations adjusted for PPP)
0.260 MT / 
Million
1.3891 MT / 
Million USD
Waste intensity in terms of physical output (Total Waste 
Generated / Physical Output)
0.0001 MT / 
Production in Kgs
0.0003 MT / 
Production in Kgs
Waste intensity (optional) the relevant metric may be selected 
by the entity
-
-
SUPRIYA 
LIFESCIENCE LTD. 
Corporate Overview
Statutory Reports
Financial Section
127
Parameter
FY2024-25
FY2023-24
For each category of waste generated, total waste recovered 
through recycling, re-using or other recovery operations (in 
metric tonnes)
Category of waste - Plastic
(i)	 Recycled
0.0000
0.0000
(ii)	 Re-used
0.0000
0.0000
(iii)	 Other recovery operations
0.0000
0.0000
Total Plastic Waste Recycled, Re-used and other recovery 
operations
0.0000
0.0000
Category of waste - E-Waste
(i)eRecycled
0.0000
0.0000
(ii)	 Re-used
0.0000
0.0000
(iii)	 Other recovery operations
0.0000
0.0000
Total E-Waste Recycled, Re-used and other recovery operations
0.0000
0.0000
Category of waste - Bio-medical waste
(i)eRecycled
0.0000
0.0000
(ii)	 Re-used
0.0000
0.0000
(iii)	 Other recovery operations
0.0000
0.0000
Total Bio-medical Waste Recycled, Re-used and other recovery 
operations
0.0000
0.0000
Category of waste - Construction and demolition waste
(i)	 Recycled
0.0000
0.0000
(ii)	 Re-used
0.0000
0.0000
(iii)	 Other recovery operations
0.0000
0.0000
Total Construction Waste Recycled, Re-used and other recovery 
operations
0.0000
0.0000
Category of waste - Battery waste
(i)	 Recycled
0.0000
0.0000
(ii)	 Re-used
0.0000
0.0000
(iii)	 Other recovery operations
0.0000
0.0000
Total Battery Waste Recycled, Re-used and other recovery 
operations
0.0000
0.3100
Category of waste - Radioactive waste
(i)	 Recycled
0.0000
0.0000
(ii)	 Re-used
0.0000
0.0000
(iii)	 Other recovery operations
0.0000
0.0000
Total Radioactive Waste Recycled, Re-used and other recovery 
operations
0.0000
0.0000
Category of waste - Other Hazardous waste
(i)	 Recycled
0.0000
0.0000
(ii)	 Re-used
0.0000
0.0000
(iii)	 Other recovery operations
38.2000
0.0000
Total Other Hazardous Waste Recycled, Re-used and other 
recovery operations
38.2000
0.0000
Category of waste - Other Non-Hazardous waste
(i)	 Recycled
0.0000
0.0000
(ii)	 Re-used
0.0000
0.0000
(iii)	 Other recovery operations
0.0000
0.0000
Total Other Non-hazardous Waste Recycled, Re-used and other 
recovery operations
0.0000
0.0000
Total
38.2000
0.0000
Supriya Lifescience Ltd.   |   Annual Report 2024-25   |   128
Parameter
FY2024-25
FY2023-24
For each category of waste generated, total waste disposed by 
nature of disposal method (in metric tonnes)
Category of waste - Plastic
(i)	 Incineration
0.0000
0.0000
(ii)	 Landfilling
0.0000
0.0000
(iii)	 Other disposal operations
12.0000
12.0000
Total Plastic Waste Incineration, Landfilling and other disposal 
operations
12.0000
12.0000
Category of waste - E-Waste
(i)	 Incineration
0.0000
0.0000
(ii)	 Landfilling
0.0000
0.0000
(iii)	 Other disposal operations
0.1060
0.8000
Total E-waste Waste Incineration, Landfilling and other disposal 
operations
0.1060
0.8000
Category of waste - Bio-medical Waste
(i)	 Incineration
0.8400
0.0001
(ii)	 Landfilling
0.0000
0.0000
(iii)	 Other disposal operations
0.0008
0.0014
Total Bio-medical Waste Incineration, Landfilling and other 
disposal operations
0.8408
0.0015
Category of waste - Construction and demolition waste
(i)	 Incineration
0.0000
0.0000
(ii)	 Landfilling
0.0000
0.0000
(iii)	 Other disposal operations
0.0000
0.0000
Total Construction Waste Incineration, Landfilling and other 
disposal operations
0.0000
0.0000
Category of waste - Battery
(i)	 Incineration
0.0000
0.0000
(ii)	 Landfilling
0.0000
0.0000
(iii)	 Other disposal operations
0.0000
0.0000
Total Battery Waste Incineration, Landfilling and Other disposal 
operations
0.0000
0.0000
Category of waste - Radioactive
(i)	 Incineration
0.0000
0.0000
(ii)	 Landfilling
0.0000
0.0000
(iii)	 Other disposal operations
0.0000
0.0000
Total Radioactive Waste Incineration, Landfilling and Other 
disposal operations
0.0000
0.0000
Category of waste - Other Hazardous waste. Please specify, if 
any
(i)	 Incineration
7.8300
0.000
(ii)	 Landfilling
29.5700
0.000
(iii)	 Other disposal operations
0.0000
13.000
Total Other Hazardous Waste Incineration, Landfilling and Other 
disposal operations
37.4000
13.000
Category of waste - Other Non-hazardous waste generated
(i)	 Incineration
0.0000
0.0000
(ii)	 Landfilling
0.0000
320.00
(iii)	 Other disposal operations
0.0000
0.0000
Total Other Non-hazardous Waste Incineration, Landfilling and 
Other disposal operations
0.0000
0.0000
Total
38.3468
320.00
SUPRIYA 
LIFESCIENCE LTD. 
Corporate Overview
Statutory Reports
Financial Section
129
9. 	 Indicate if any independent assessment/evaluation/assurance for Waste has been conducted by an external 
agency. If Yes, provide the name of the agency:
Yes. Maharashtra Pollution control Board
10. 	Briefly describe the waste management practices adopted in your establishments. Describe the strategy 
adopted by your company to reduce usage of hazardous and toxic chemicals in your products and processes 
and the practices adopted to manage such wastes.
Waste management practices adopted in our establishment like reduction, reuse, recycling, and proper disposal 
methods like incineration and landfilling. strategy adopted by our organization to substitution with less harmful 
alternatives, process optimization to minimize waste generation, engineering and administrative controls, along 
with robust safety protocols.
11. 	If the entity has operations/offices in/around ecologically sensitive areas (such as national parks, wildlife 
sanctuaries, biosphere reserves, wetlands, biodiversity hotspots, forests, coastal regulation zones etc.) 
where environmental approvals / clearances are required:
S. 
No.
Location of operations/
offices
Type of 
operations
Whether the conditions of environmental approval / 
clearance are being complied with? (Y/N) If no, the 
reasons thereof and corrective action taken, if any.
1
Facility located at MIDC Lote 
Maharashtra
Manufacturing
Yes
12. 	Details of environmental impact assessments of projects undertaken by the entity based on applicable laws, 
in the current financial year:
S. 
No.
Name and 
brief details of 
project
EIA Notification 
No.
Date
Whether conducted 
by independent 
external agency 
(Yes / No)
Results 
communicated 
in public domain 
(Yes / No)
Relevant 
Web link
1
-
-
-
-
-
-
13. 	Is the entity compliant with the applicable environmental law/ regulations/ guidelines in India; such as the 
Water (Prevention and Control of Pollution) Act, Air (Prevention and Control of Pollution) Act, Environment 
protection act and rules thereunder (Y/N). If not, provide details of all such non-compliances:
S. 
No.
Specify the law / regulation / guidelines 
which was not complied with
Provide 
details of 
the non-
compliance
Any fines / penalties / action 
taken by regulatory agencies 
such as pollution control 
boards or by courts
Corrective 
action 
taken, if any
1
Water (Prevention & Control of Pollution) 
Act, 1974,Air (Prevention & Control of 
Pollution) Act, 1981, Hazardous & Other 
Wastes (Management & Transboundary 
Movement) Rules 2016 
No
No
-
Supriya Lifescience Ltd.   |   Annual Report 2024-25   |   130
Leadership Indicators
1. 	 Water withdrawal, consumption and discharge in areas of water stress (in kilolitres):
(i) 	 Name of the area
(ii) 	Nature of operations
(iii)	Water withdrawal, consumption and discharge in areas of water stress (in kilolitres) for the current year: 
Water withdrawal, and discharge:
Parameter
FY2024-25
FY2023-24
Water withdrawal by source (in kilolitres)
(i) 	 Surface water
0
0
(ii) eGroundwater
0
0
(iii) 	Third party water
0
0
(iv) eSeawater / desalinated water
0
0
(v) 	Others
0
0
Total volume of water withdrawal(in kilolitres)
0
0
Total volume of water consumption (in kilolitres)
0.00
0.00
Water intensity per rupee of turnover (Water consumed / 
turnover)
0.0000 KL / 
Million
0.0000 KL / 
Million
Water intensity (optional) – the relevant metric may be selected 
by the entity. KL / of 
NaN
NaN
Water discharge by destination and level of treatment (in 
kilolitres)
(i) 	 Into Surface water
- 	
No treatment
0.00
0.00
- 	
With treatment – please specify level of treatment
0.00 
CY:0
0.00 
PY:0
(ii) 	Into Groundwater
- 	
No treatment
0.00
0.00
- 	
With treatment – please specify level of treatment
0.00
CY:0
0.00
PY:0
(iii) 	Into Seawater
- 	
No treatment
0.00
0.00
- 	
With treatment – please specify level of treatment
0.00
CY:0
0.00
PY:0
(iv) 	Sent to third-parties
- 	
No treatment
0.00
0.00
- 	
With treatment – please specify level of treatment
0.00
CY:0
0.00
PY:0
(v) 	Others
- 	
No treatment
0.00
0.00
- 	
With treatment – please specify level of treatment
0.00
CY:0
0.00
PY:0
Total water discharged (in kilolitres)
0.00
0.00
1. 	 Indicate if any independent assessment/ evaluation/assurance has been carried out by an external agency? 
(Y/N) If yes, name of the external agency.
No. 
SUPRIYA 
LIFESCIENCE LTD. 
Corporate Overview
Statutory Reports
Financial Section
131
2.	  Please provide details of total Scope 3 emissions (MTCO2E) & its intensity:
Parameter
FY2024-25
FY2023-24
Total Scope 3 emissions
(Break-up of the GHG into CO2, CH4, N2O, HFCs, PFCs, SF6, NF3, if 
available)
Total Scope 3 emissions per rupee of turnover
0.00 TCO2e / 
Million
0.00 TCO2e / 
Million
Total Scope 3 emission intensity (optional) – the relevant metric may 
be selected by the entity
0.00 TCO2e /
0.00 TCO2e /
2. 	 Indicate if any independent assessment/ evaluation/assurance has been carried out by an external agency? 
(Y/N) If yes, name of the external agency. -
3. 	 With respect to the ecologically sensitive areas reported at EI-11 above, provide details of the significant 
direct & indirect impact of the entity on biodiversity in such areas along with prevention and remediation 
activities.
Not applicable, as none of the manufacturing units is in ecologically sensitive zones
4. 	 If the entity has undertaken any specific initiatives or used innovative technology or solutions to improve 
resource efficiency, or reduce impact due to emissions / effluent discharge / waste generated, please 
provide details of the same as well as outcome of such initiatives:
S. 
No.
Initiative 
undertaken
Details of the initiative (Web-link, if any, may be 
provided along-with summary)
Outcome of the initiative
1
Scrubbers used for 
gases pollution.
1.	 Generated gases from process will scrub in 
scrubbing media
Achieving Standards set in the 
industry from an internal and 
external perspective
2
Effluent Treatment 
Plant
2. 	 Generated effluent treating in own effluent 
treatment facility and sending towards common 
effluent treatment plant for further treatment
Achieving Standards set in the 
industry from an internal and 
external perspective
5. 	 Does the entity have a business continuity and disaster management plan? If yes, please give details in 100 
words or input web link.
Yes
6. 	 Disclose any significant adverse impact to the environment, arising from the value chain of the entity. What 
mitigation or adaptation measures have been taken by the entity in this regard.
Not Applicable
7. 	 Percentage of value chain partners (by value of business done with such partners) that were assessed for 
environmental impacts.
Not Applicable
8. 	 How many Green Credits have been generated or procured?
a. 	 Generated by the listed entity - 0
b 	 Procured by the top ten (in terms of value of purchases and sales, respectively) value chain partners - 0
Supriya Lifescience Ltd.   |   Annual Report 2024-25   |   132
PRINCIPLE 7: Businesses, when engaging in influencing public and regulatory policy, should do so in a 
manner that is responsible and transparent
Essential Indicators
1.	 a.	 Number of affiliations with trade and industry chambers/ associations.
5
b. 	 List the top 10 trade and industry chambers/ associations (determined based on the total members of 
such body) the entity is a member of/ affiliated to. 
S. 
No.
Name of the trade and industry chambers/associations
Reach of trade and industry 
chambers/associations (State/
National/International)
1
Chemicals Export Promotion Council (CHEMEXCIL)
National
2
Pharmaceutical Export Promotion Council of India 
(PHARMEXCIL)
National
3
Federation of Indian Export Organisations (FIEO)
National
4
Maharashtra Chamber of Commerce, Industry & Agriculture 
(MACCIA)
State
5
IMC Chamber of Commerce and Industry
National
2. 	 Provide details of corrective action taken or underway on any issues related to anti-competitive conduct by 
the entity, based on adverse orders from regulatory authorities.
S. 
No.
Name of authority
Brief of the case
Corrective action taken
1
NA
Leadership Indicators
1. 	 Details of public policy positions advocated by the entity:
S. 
No.
Public policy 
advocated
Method 
resorted for 
such advocacy
Whether information 
available in public 
domain? (Yes/No)
Frequency of 
Review by Board 
Web Link, if available
1
NA
PRINCIPLE 8: Businesses should promote inclusive growth and equitable development
Essential Indicators
1. 	 Details of Social Impact Assessments (SIA) of projects undertaken by the entity based on applicable laws, in 
the current financial year.
S. 
No.
Name and 
brief details of 
project
SIA Notification 
No.
Date of 
notification
Whether conducted 
by independent 
external agency 
(Yes / No)
Results 
communicated 
in public domain 
(Yes / No)
Relevant 
Web link
1
-
-
-
-
-
-
SUPRIYA 
LIFESCIENCE LTD. 
Corporate Overview
Statutory Reports
Financial Section
133
2. 	 Provide information on project(s) for which ongoing Rehabilitation and Resettlement (R&R) is being 
undertaken by your entity:
S. 
No.
Name of Project 
for which R&R is 
ongoing
State
District
No. of Project 
Affected Families 
(PAFs)
% of PAFs 
covered by R&R
Amounts paid to 
PAFs in the Financial 
Year (In INR)
1
NA
3. 	 Describe the mechanisms to receive and redress grievances of the community.
There is a Point of Contact from the CSR team whom the community can go to report any grievances. The 
POC visits the community on a regular basis for monitoring of CSR projects, and also conducts stakeholder 
engagement with the community members.
4. 	 Input material sourced from suppliers (by value):
Category
Current 
Financial Year
Previous 
Financial Year
Directly sourced from MSMEs/ small producers
40%
37%
Sourced directly from within India
80%
58%
5. 	 Job creation in smaller towns- Disclose wages paid to persons employed (including employees or workers 
employed on a permanent or non-permanent/on contract basis) in the following locations, as % of total wage 
cost. (Place to be categorized as per RBI Classification System - rural / semi-urban / urban / metropolitan)
Location
Current 
Financial Year
Previous 
Financial Year
Rural
31.22%
29.80%
Semi-Urban
0.00%
0.00%
Urban
9.06%
3.02%
Metropolitan
40.33%
67.18%
Leadership Indicators
1. 	 If any Social Impact Assessments have been reported in EI-1, please provide details of actions taken to 
mitigate any negative social impacts identified:
S. 
No.
Details of negative social impact identified
Corrective action taken
1
NA
2. 	 Provide the following information on CSR projects undertaken by your entity in designated aspirational 
districts as identified by government bodies:
S. 
No.
State
Aspirational District
Amount spent (In INR)
1
NA
3.	 a. 	 Do you have a preferential procurement policy where you give preference to purchase from suppliers 
comprising marginalized /vulnerable groups? (Yes/No) - No
b. 	 From which marginalized /vulnerable groups do you procure? - No
c. 	 What percentage of total procurement (by value) does it constitute? – Not Applicable
Supriya Lifescience Ltd.   |   Annual Report 2024-25   |   134
4. 	 Details of the benefits derived and shared from the intellectual properties owned or acquired by your entity 
(in the current financial year), based on traditional knowledge:
S. 
No.
Intellectual Property based on 
traditional knowledge
Owned/ Acquired 
(Yes/No)
Benefit shared 
(Yes / No)
Basis of calculating 
benefit share
1
NA
5. 	 Details of corrective actions taken or underway, based on any adverse order in intellectual property-related 
disputes wherein usage of traditional knowledge is involved.
S. No.
Name of authority
Brief of the Case
Corrective action taken
1
NA
6. 	 Details of beneficiaries of CSR Projects:
S. 
No.
CSR Project
No. of persons benefitted 
from CSR Projects
% of beneficiaries 
from vulnerable and 
marginalized groups
1
Promoting Education
1300
80
2
Rural Development
2000
90
3
Environmental Sustainability & Animal Welfare
10000
NA
4
Preventive health care and sanitation
1200
90
PRINCIPLE 9: Businesses should engage with and provide value to their consumers in a responsible manner
Essential Indicators
1. 	 Describe the mechanisms in place to receive and respond to consumer complaints and feedback.
All customer complaints are processed by a cross-functional team comprising QA, R&D, and Marketing 
departments, in compliance with internal protocols. Complaints are received by the Marketing team and 
forwarded to QA, which acknowledges receipt and initiates a formal investigation. QA requests all pertinent 
information, including invoice and batch details, from Marketing and other concerned departments. After a 
complete investigation, QA prepares a CAPA report, which is relayed to the customer through the Marketing 
team. Ongoing customer feedback is solicited to assess and improve compliance with quality standards and 
service performance.
2. 	 Turnover of products and/ services as a percentage of turnover from all products/service that carry 
information about:
Category
As a percentage to total turnover
Environmental and social parameters relevant to the product
70%
Safe and responsible usage
20%
Recycling and/or safe disposal
10%
SUPRIYA 
LIFESCIENCE LTD. 
Corporate Overview
Statutory Reports
Financial Section
135
3. 	 Number of consumer complaints in respect of the following:
FY2024-25
FY2023-24
Received 
during the 
year
Pending 
resolution at end 
of year
Remarks
Received 
during the 
year
Pending 
resolution at 
end of year
Remarks
Data privacy
0
0
0
0
0
0
Advertising
0
0
0
0
0
0
Cyber-security
0
0
0
0
0
0
Delivery of essential 
services
0
0
0
0
0
0
Restrictive Trade 
Practices
0
0
0
0
0
0
Unfair Trade 
Practices
0
0
0
0
0
0
Other
0
0
0
0
0
0
4. 	 Details of instances of product recalls on account of safety issues:
Category
Number
Reasons for recall
Voluntary recalls
0
-
Forced recalls
2
Requirement deferred by customer
5. 	 Does the entity have a framework/ policy on cyber security and risks related to data privacy? (Yes/No) If 
available, provide a web-link of the policy.
Yes. 
https://supriyalifescience.com/assets/pdfs/corporate-governance/policies/Information%20Security%20
Policy.pdf
6. 	 Provide details of any corrective actions taken or underway on issues relating to any of the following: i. 
Advertising; ii. Delivery of essential services; iii. Cyber security and data privacy of customers; iv. Re-
occurrence of instances of product recalls V. penalty / action taken by regulatory authorities on safety of 
products / services.
No corrective actions have been taken or underway since no such incidents have been reported in any of the 
following criteria
7. 	 Provide the following information relating to data breaches:
a. 	 Number of instances of data breaches
Nil
b. 	 Percentage of data breaches involving personally identifiable information of customers
Not Applicable
c. 	 Impact, if any, of the data breaches
Not Applicable
Supriya Lifescience Ltd.   |   Annual Report 2024-25   |   136
1. 	 Channels/platforms where information on products and services of the entity can be accessed (provide web 
link, if available).
Information of various products can be accessed on Company's website www.supriyalifescience.com
2. 	 Steps taken to inform and educate consumers about safe and responsible usage of products and/or services.
Material safety data sheets are shared with the customer for each product.
3. 	 Mechanisms in place to inform consumers of any risk of disruption/discontinuation of essential services
Any product disruptions or change in plan are informed to the customers in advance.
4. 	 Does the entity display product information on the product over and above what is mandated as per local 
laws? (Yes/No/Not Applicable) If yes, provide details in brief. Did your entity carry out any survey with 
regard to consumer satisfaction relating to the major products / services of the entity, significant locations 
of operation of the entity or the entity as a whole? (Yes/No)
Not applicable for APIs.. The Company ensures customer satisfaction by issuing a checklist of key compliance 
parameters in accordance with the Drugs and Cosmetics Act. The Quality Department is tasked with maintaining 
and updating the Customer Satisfaction Index in line with applicable laws and client-specific requirements.
Leadership Indicators
SUPRIYA 
LIFESCIENCE LTD. 
